Impact of "off-Label" Use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 4, 2010, Pages 349-355

  Sarullo, Filippo M ^a   Fazio, Giovanni ^b   Puccio, Danilo ^a   Fasullo, Sergio ^c   Paterna, Salvatore ^b   Novo, Salvatore ^b   Di Pasquale, Pietro ^c  

^a Buccheri La Ferla Fatebenefratelli Hospital   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Ospedale GF Ingrassia   (Italy)

Author keywords

congestive heart failure; exercise capacity; gas exchange; off label ivabradine use

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRONCHODILATING AGENT; CARVEDILOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; LISINOPRIL; PLACEBO;

ADULT; AGED; ANAEROBIC THRESHOLD; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ECHOCARDIOGRAPHY; ENDURANCE TRAINING; EXERCISE; EXERCISE TEST; FEMALE; GAS ANALYSIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE ISCHEMIA; HORMONAL REGULATION; HUMAN; LUNG GAS EXCHANGE; MAJOR CLINICAL STUDY; MALE; OBSTRUCTIVE AIRWAY DISEASE; OFF LABEL DRUG USE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VISUAL DISORDER; WORKLOAD;

ADRENERGIC BETA-ANTAGONISTS; BENZAZEPINES; CHRONIC DISEASE; EXERCISE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; NEUROTRANSMITTER AGENTS; OFF-LABEL USE; OXYGEN CONSUMPTION; QUALITY OF LIFE;

EID: 78651275247     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410370326     Document Type: Article

References (32)

1. McMurray JJ, Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 ; 362 (9386). 767-771.
2. Granger CB, McMurray JJ, Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 ; 362 (9386). 772-776.
3. Poole-Wilson PA, Swedberg K., Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003 ; 362 (9377). 7-13.
4. Kannel WB, Kannel C., Paffenbarger Rsjr, Cupples LA Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987 ; 113 (6). 1489-1494.
5. Fox K., Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007 ; 50 (9). 823-830.
6. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007 ; 28: 2375-2414.
7. Palatini P., Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens. 2004 ; 26 (7-8). 637-644.
8. Pocock SJ, Wang D., Pfeffer MA, et al. Predictor of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006 ; 27 (1). 65-75.
9. Fox K., Ford I., Steg PG, Tendera M., Robertson M., Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008 ; 372 (9641). 817-821.
10. Lechat P., Hulot JS, Escolano S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001 ; 103 (10). 1428-1433.
11. Di Francesco D. I (f) inhibition: a novel mechanism of action. Eur Heart J. 2003 ; 5 (suppl G). G19 - G25.
12. Di Francesco D., Camm JA Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004 ; 64 (16). 1757-1765.
13. Mulder P., Barbier S., Chagraoui A., et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function ad intrinsic myocardial structure in congestive heart failure. Circulation. 2004 ; 109 (13). 1674-1679.
14. Beaver WL, Wasserman K., Whipp BJ A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol. 1986 ; 60 (6). 2020-2027.
15. Schiller NB, Shah PM, Crawford M., et al. Recommendations for quantitation of left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards and Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989 ; 2 (5). 358-367.
16. Rector TS, Cohn JN with the Pimobendan Multicenter Research Group. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-bind, placebo-controlled trial of pimobendan. Am Heart J. 1992 ; 124 (4). 1017-1025.
17. Belardinelli R., Georgiou D., Cianci G., Purcaro A. Randomized controlled trial of long-term moderate exercise training in chronic heart failure. Effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999 ; 99 (9). 1173-1182.
18. Hubo SH, Gollub S., Buorge R., et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation. 1992 ; 85 (3). 942-949.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285 (19). 2486-2497.
20. Benetos A., Thomas F., Bean K., et al. Resting heart rate in older people: a predictor of survival to 85. J Am Geriatr Soc. 2003 ; 51 (2). 284-285.
21. Manz M., Reuter M., Lauck G., Omran H., Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003 ; 100 (3). 149-155.
22. Borer JS, Fox K., Jaillon P., Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003 ; 107 (6). 817-823.
23. De Ferrari GM, Mazzuero A., Agnesina L., et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008 ; 10 (6). 550-555.
24. Custodis F., Baumhäkel M., Schlimmer N., et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008 ; 117 (18). 2377-2387.
25. Hjalmarson A., Gilpin EA, Kjekshus J., et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990 ; 65 (9). 547-553.
26. Singh N. Diabetes, heart rate, and mortality. J Cardiovasc Pharmacol Ther. 2002 ; 7 (2). 117-129.
27. Gundersen T., Grottum P., Pedersen T., et al. Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol. 1989 ; 58 (1). 20-24.
28. Kjekshus JK Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986 ; 57 (12). 43 F-49F.
29. Kjekshus JK Heart rate reduction: a mechanism of benefit? Eur Heart J. 1987 ; 8 (suppl L). 115-122.
30. Hjalmarson A. Significance of reduction in heart rate in cardiovascular disease. Clin Cardiol. 1998 ; 21 (12 suppl II). 113-117.
31. Colin P., Ghaleh B., Monnet X., et al. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther. 2004 ; 308 (1). 236-240.
32. Metra M., Nardi M., Giubbini R., et al. Effects of short and long term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994 ; 24 (7). 1678-1687.